NCT00003496 - Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 7, 1996

Primary Completion Date

February 5, 2004

Study Completion Date

February 5, 2004

Conditions

Small Cell Lung Cancer Extensive Stage

Interventions

DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Patients with Recurrent or Extensive-Stage Small Cell Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston